PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)30.90 %Percentage2013/2014_Q12013-04-012013-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)34.60 %Percentage2013/20142013-04-012014-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)31.10 %Percentage2013/2014_Q22013-07-012013-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)30.50 %Percentage2013/2014_Q32013-10-012013-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)34.60 %Percentage2013/2014_Q42014-01-012014-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)36.50 %Percentage2014/2015_Q12014-04-012014-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)40.10 %Percentage2014/20152014-04-012015-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)35.60 %Percentage2014/2015_Q22014-07-012014-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)38.80 %Percentage2014/2015_Q32014-10-012014-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)40.10 %Percentage2014/2015_Q42015-01-012015-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)38.00 %Percentage2015/2016_Q12015-04-012015-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)31.10 %Percentage2015/20162015-04-012016-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)34.80 %Percentage2015/2016_Q22015-07-012015-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)33.30 %Percentage2015/2016_Q32015-10-012015-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)31.10 %Percentage2015/2016_Q42016-01-012016-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)32.51 %Percentage2016/2017_Q12016-04-012016-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)38.08 %Percentage2016/20172016-04-012017-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)37.93 %Percentage2016/2017_Q22016-07-012016-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)37.89 %Percentage2016/2017_Q32016-10-012016-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)38.08 %Percentage2016/2017_Q42017-01-012017-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)32.11 %Percentage2017/20182017-04-012018-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)36.93 %Percentage2017/2018_Q12017-04-012017-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)33.91 %Percentage2017/2018_Q22017-07-012017-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.96 %Percentage2017/2018_Q32017-10-012017-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)32.11 %Percentage2017/2018_Q42018-01-012018-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.20 %Percentage2018/20192018-04-012019-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)30.33 %Percentage2018/2019_Q12018-04-012018-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)26.61 %Percentage2018/2019_Q22018-07-012018-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)31.50 %Percentage2018/2019_Q32018-10-012018-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.20 %Percentage2018/2019_Q42019-01-012019-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)28.71 %Percentage2019/2020_Q12019-04-012019-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)27.71 %Percentage2019/20202019-04-012020-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)32.49 %Percentage2019/2020_Q22019-07-012019-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)31.84 %Percentage2019/2020_Q32019-10-012019-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)27.71 %Percentage2019/2020_Q42020-01-012020-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.30 %Percentage2020/20212020-04-012021-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.30 %Percentage2020/2021_Q12020-04-012020-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)27.67 %Percentage2020/2021_Q22020-07-012020-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)28.97 %Percentage2020/2021_Q32020-10-012020-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.30 %Percentage2020/2021_Q42021-01-012021-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)26.50 %Percentage2021/20222021-04-012022-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)27.61 %Percentage2021/2022_Q12021-04-012021-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.70 %Percentage2021/2022_Q22021-07-012021-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)28.73 %Percentage2021/2022_Q32021-10-012021-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)26.50 %Percentage2021/2022_Q42022-01-012022-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)20.00 %Percentage2022/20232022-04-012023-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)24.78 %Percentage2022/2023_Q12022-04-012022-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)21.40 %Percentage2022/2023_Q22022-07-012022-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)19.92 %Percentage2022/2023_Q32022-10-012022-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)20.00 %Percentage2022/2023_Q42023-01-012023-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)21.99 %Percentage2023/2024_Q12023-04-012023-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)19.52 %Percentage2023/20242023-04-012024-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)22.22 %Percentage2023/2024_Q22023-07-012023-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)23.30 %Percentage2023/2024_Q32023-10-012023-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)19.52 %Percentage2023/2024_Q42024-01-012024-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)16.50 %Percentage2024/2025_Q12024-04-012024-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)17.14 %Percentage2024/20252024-04-012025-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)17.70 %Percentage2024/2025_Q22024-07-012024-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)15.84 %Percentage2024/2025_Q32024-10-012024-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)17.14 %Percentage2024/2025_Q42025-01-012025-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)18.72 %Percentage2025/2026_Q12025-04-012025-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)23.59 %Percentage2025/2026_Q22025-07-012025-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)30.90 %Percentage2013/2014_Q12013-04-012013-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)34.60 %Percentage2013/20142013-04-012014-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)31.10 %Percentage2013/2014_Q22013-07-012013-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)30.50 %Percentage2013/2014_Q32013-10-012013-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)34.60 %Percentage2013/2014_Q42014-01-012014-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)36.50 %Percentage2014/2015_Q12014-04-012014-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)40.10 %Percentage2014/20152014-04-012015-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)35.60 %Percentage2014/2015_Q22014-07-012014-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)38.80 %Percentage2014/2015_Q32014-10-012014-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)40.10 %Percentage2014/2015_Q42015-01-012015-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)38.00 %Percentage2015/2016_Q12015-04-012015-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)31.10 %Percentage2015/20162015-04-012016-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)34.80 %Percentage2015/2016_Q22015-07-012015-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)33.30 %Percentage2015/2016_Q32015-10-012015-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)31.10 %Percentage2015/2016_Q42016-01-012016-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)32.51 %Percentage2016/2017_Q12016-04-012016-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)38.08 %Percentage2016/20172016-04-012017-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)37.93 %Percentage2016/2017_Q22016-07-012016-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)37.89 %Percentage2016/2017_Q32016-10-012016-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)38.08 %Percentage2016/2017_Q42017-01-012017-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)32.11 %Percentage2017/20182017-04-012018-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)36.93 %Percentage2017/2018_Q12017-04-012017-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)33.91 %Percentage2017/2018_Q22017-07-012017-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.96 %Percentage2017/2018_Q32017-10-012017-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)32.11 %Percentage2017/2018_Q42018-01-012018-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.20 %Percentage2018/20192018-04-012019-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)30.33 %Percentage2018/2019_Q12018-04-012018-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)26.61 %Percentage2018/2019_Q22018-07-012018-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)31.50 %Percentage2018/2019_Q32018-10-012018-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.20 %Percentage2018/2019_Q42019-01-012019-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)28.71 %Percentage2019/2020_Q12019-04-012019-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)27.71 %Percentage2019/20202019-04-012020-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)32.49 %Percentage2019/2020_Q22019-07-012019-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)31.84 %Percentage2019/2020_Q32019-10-012019-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)27.71 %Percentage2019/2020_Q42020-01-012020-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.30 %Percentage2020/20212020-04-012021-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.30 %Percentage2020/2021_Q12020-04-012020-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)27.67 %Percentage2020/2021_Q22020-07-012020-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)28.97 %Percentage2020/2021_Q32020-10-012020-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.30 %Percentage2020/2021_Q42021-01-012021-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)26.50 %Percentage2021/20222021-04-012022-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)27.61 %Percentage2021/2022_Q12021-04-012021-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)29.70 %Percentage2021/2022_Q22021-07-012021-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)28.73 %Percentage2021/2022_Q32021-10-012021-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)26.50 %Percentage2021/2022_Q42022-01-012022-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)20.00 %Percentage2022/20232022-04-012023-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)24.78 %Percentage2022/2023_Q12022-04-012022-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)21.40 %Percentage2022/2023_Q22022-07-012022-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)19.92 %Percentage2022/2023_Q32022-10-012022-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)20.00 %Percentage2022/2023_Q42023-01-012023-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)21.99 %Percentage2023/2024_Q12023-04-012023-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)19.52 %Percentage2023/20242023-04-012024-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)22.22 %Percentage2023/2024_Q22023-07-012023-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)23.30 %Percentage2023/2024_Q32023-10-012023-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)19.52 %Percentage2023/2024_Q42024-01-012024-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)16.50 %Percentage2024/2025_Q12024-04-012024-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)17.14 %Percentage2024/20252024-04-012025-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)17.70 %Percentage2024/2025_Q22024-07-012024-09-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)15.84 %Percentage2024/2025_Q32024-10-012024-12-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)17.14 %Percentage2024/2025_Q42025-01-012025-03-31Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)18.72 %Percentage2025/2026_Q12025-04-012025-06-30Quarterly PHOF77% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)23.59 %Percentage2025/2026_Q22025-07-012025-09-30Quarterly